Small cell lung cancer exhibits rapid proliferation and significant metastatic potential. There are significant epidemiologic and biological associations with tobacco carcinogens. While most small cell lung cancers display neuroendocrine characteristics, a significant subset of tumors does not possess these features. Genomic profiling of small cell lung cancer demonstrates genetic instability, nearly universal inactivation of the tumor suppressor genes TP53 and RB1, and a significant mutation burden. Due to early metastasis, a limited number of patients are suitable for curative lung resection, necessitating adjuvant platinum-etoposide chemotherapy for these individuals. Consequently, most patients are presently receiving chemoradiation, with or without the addition of immunotherapy. For patients with disease localized to the chest, standard treatment comprises thoracic radiotherapy alongside concurrent platinum-etoposide chemotherapy. Patients diagnosed with metastatic disease receive treatment that combines platinum-etoposide chemotherapy with immunotherapy utilizing an anti-programmed death-ligand 1 monoclonal antibody. Small cell lung cancer initially exhibits a strong response to platinum-based chemotherapy; however, these responses are temporary due to the emergence of drug resistance. Recent years have seen an accelerated accumulation of biological insights into the disease, resulting in a redefinition of the classification scheme for small cell lung cancer. The emerging understanding of molecular subtypes in small cell lung cancer may delineate distinct therapeutic vulnerabilities. The integration of these recent findings with existing knowledge of small cell lung cancer biology and clinical management could result in significant improvements in patient care for this condition. The authors provide an overview of multimodal clinical approaches in small cell lung cancer, emphasizing recent advancements in research that may expedite clinical development.
Define, C. Future directions of diagnostic and therapeutic strategies specific to subtypes of small cell lung cancer. International Journal of Clinical Medical Research, 2025, 3, 50. https://doi.org/10.61466/ijcmr3010005
AMA Style
Define C. Future directions of diagnostic and therapeutic strategies specific to subtypes of small cell lung cancer. International Journal of Clinical Medical Research; 2025, 3(1):50. https://doi.org/10.61466/ijcmr3010005
Chicago/Turabian Style
Define, Carl 2025. "Future directions of diagnostic and therapeutic strategies specific to subtypes of small cell lung cancer" International Journal of Clinical Medical Research 3, no.1:50. https://doi.org/10.61466/ijcmr3010005
APA style
Define, C. (2025). Future directions of diagnostic and therapeutic strategies specific to subtypes of small cell lung cancer. International Journal of Clinical Medical Research, 3(1), 50. https://doi.org/10.61466/ijcmr3010005
Article Metrics
Article Access Statistics
References
Siegel, R.L., Miller, K.D., Fuchs, H.E., et al., Cancer statistics, 2022. CA Cancer J Clin, 2022. 72(1): p. 7-33.
Rudin, C.M., Brambilla, E., Faivre-Finn, C., et al., Small-cell lung cancer. Nat Rev Dis Primers, 2021. 7(1): p. 3.
Jordan, E.J., Kim, H.R., Arcila, M.E., et al., Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discov, 2017. 7(6): p. 596-609.
Rudin, C.M., Poirier, J.T., Byers, L.A., et al., Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer, 2019. 19(5): p. 289-297.
Barnard, W.G., The nature of the “oat-celled sarcoma” of the mediastinum. J Pathol Bacteriol, 1926. 29(3): p. 241-244.
Haddadin, S. and Perry, M.C., History of small-cell lung cancer. Clin Lung Cancer, 2011. 12(2): p. 87-93.
Matthews, M.J., Kanhouwa, S., Pickren, J., et al., Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer. Cancer Chemother Rep 3, 1973. 4(2): p. 63-7.
Karim, S.M. and Zekri, J., Chemotherapy for small cell lung cancer: a comprehensive review. Oncol Rev, 2012. 6(1): p. e4.
Rudin, C.M. and Poirier, J.T., Small-cell lung cancer in 2016: Shining light on novel targets and therapies. Nat Rev Clin Oncol, 2017. 14(2): p. 75-76.
Hirsch, F.R., Hansen, H.H., Hansen, M., et al., The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients. J Clin Oncol, 1987. 5(4): p. 585-91.
Ragavan, M. and Das, M., Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy. Curr Treat Options Oncol, 2020. 21(8): p. 64.
Gazdar, A.F., Bunn, P.A., and Minna, J.D., Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer, 2017. 17(12): p. 725-737.
Poirier, J.T., George, J., Owonikoko, T.K., et al., New Approaches to SCLC Therapy: From the Laboratory to the Clinic. J Thorac Oncol, 2020. 15(4): p. 520-540.
Heeke, S., Gay, C., Estecio, M., et al., MA01. 03 exploiting DNA methylation for classification of SCLC subtypes from liquid biopsies using a robust machine learning approach. Journal of Thoracic Oncology, 2022. 17(9): p. S43.
Chemi, F., Pearce, S.P., Clipson, A., et al., cfDNA methylome profiling for detection and subtyping of small cell lung cancers. Nat Cancer, 2022. 3(10): p. 1260-1270.
Szeitz, B., Megyesfalvi, Z., Woldmar, N., et al., In-depth proteomic analysis reveals unique subtype-specific signatures in human small-cell lung cancer. Clin Transl Med, 2022. 12(9): p. e1060.
Kim, D.W., Kim, K.C., Kim, K.B., et al., Transcriptional deregulation underlying the pathogenesis of small cell lung cancer. Transl Lung Cancer Res, 2018. 7(1): p. 4-20.
Furuta, M., Sakakibara-Konishi, J., Kikuchi, H., et al., Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702). Oncologist, 2019. 24(11): p. e1172-e1179.
Gay, C.M., Stewart, C.A., Park, E.M., et al., Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell, 2021. 39(3): p. 346-360.e7.
Jia, D., Augert, A., Kim, D.W., et al., Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov, 2018. 8(11): p. 1422-1437.
Berniker, A.V., Abdulrahman, A.A., Teytelboym, O.M., et al., Extrapulmonary small cell carcinoma: imaging features with radiologic-pathologic correlation. Radiographics, 2015. 35(1): p. 152-63.
Poirier, J.T., Dobromilskaya, I., Moriarty, W.F., et al., Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. J Natl Cancer Inst, 2013. 105(14): p. 1059-65.
Huang, Y.H., Klingbeil, O., He, X.Y., et al., POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev, 2018. 32(13-14): p. 915-928.
Winkler, A.S., Dean, A., Hu, M., et al., Phenotypic and neuropathologic heterogeneity of anti-Hu antibody-related paraneoplastic syndrome presenting with progressive dysautonomia: report of two cases. Clin Auton Res, 2001. 11(2): p. 115-8.
Schwendenwein, A., Megyesfalvi, Z., Barany, N., et al., Molecular profiles of small cell lung cancer subtypes: therapeutic implications. Mol Ther Oncolytics, 2021. 20: p. 470-483.